Harbor Capital Advisors Inc. Invests $981,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Harbor Capital Advisors Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,547 shares of the biopharmaceutical company's stock, valued at approximately $981,000.

A number of other large investors have also added to or reduced their stakes in the company. Pinney & Scofield Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $25,000. OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares in the last quarter. Tompkins Financial Corp purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. Finally, Curat Global LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $32,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded up $7.40 during midday trading on Friday, reaching $529.24. The company's stock had a trading volume of 951,512 shares, compared to its average volume of 879,349. The firm has a market capitalization of $57.14 billion, a PE ratio of 13.83, a P/E/G ratio of 2.34 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The stock's 50 day simple moving average is $563.19 and its 200 day simple moving average is $649.25.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $9.55 EPS. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on REGN. Robert W. Baird reduced their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating on the stock in a research report on Monday, June 2nd. Royal Bank of Canada cut shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a report on Friday, May 30th. Finally, Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.